Green Tea Extract Risk

UGT1A1 is the liver enzyme that conjugates EGCG — the active polyphenol in green tea extract — for clearance. CYP3A4 contributes upstream. At cup-of-tea doses, this system handles EGCG without strain. At concentrated supplement doses, the enzyme’s capacity becomes the limiting factor.

Carriers of reduced-activity UGT1A1 variants (the same variants involved in Gilbert’s syndrome) are associated with slower EGCG clearance — and a higher risk of hepatotoxicity from concentrated extract supplements. The risk scales with dose; brewed tea remains low-concern across nearly all variant patterns.

Fasting amplifies absorption and risk. Co-administration with curcumin, certain medications, or alcohol stacks the hepatic load. Adequate protein status protects hepatic glutathione, which buffers the system. Spreading doses across the day instead of single high doses reduces peak exposure.

A 500mg EGCG capsule is a different conversation from a cup of matcha — and which variant pattern you carry decides whether it’s a tolerable supplement or one to skip in favor of tea itself.